ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

conestat alfa

Also written as “Ruconest”, “Recombinant Human C1 Inhibitor” and “rhC1INH”.

Its studies are mostly in Angioedemas, Hereditary · COVID-19 · Fatigue Syndrome, Chronic, led by 2 companies.

Drug pageConestat alfa: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 20, 20058 company-led studies, 1 open or runningNext primary completion: Jul 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharming Groupits history only60 open or runningphase 3since Sep 20, 2005Sep 20, 2005none ahead
IMMUNOe Research Centers21 open or runningphase 4since Nov 6, 2026Jan 7, 2021Jul 31, 2027phase 4 · NCT07932002

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of IMMUNOe Research Centers only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 7, 2021First study: phase 2 study in Fatigue Syndrome, ChronicFirst studyNCT04705831 · 40 enrolled · United States
  2. Nov 6, 2026Phase 4 study in COVID-19NCT07932002 · 30 planned · United States

Ahead

  1. Jul 31, 2027Primary completion: phase 4 study in COVID-19NCT07932002

TargetBeta

SERPING1 →read by rule
“A recombinant form of human complement component 1 esterase inhibitor (C1INH), a serine protease inhibitor normally present in human plasma, that can be used for the treatment of hereditary angioedema (HAE)”NCIt, by rule
“Plasma protease C1 inhibitor exogenous protein”ChEMBL 37, by rule

Studies

All 2 IMMUNOe Research Centers leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07932002COVID-19 · United States4RecruitingJul 31, 202730
NCT04705831Fatigue Syndrome, Chronic · United States2CompletedMar 30, 202440

How it is read

Names in the registry

  • “Ruconest”, 3 entries
  • “Recombinant Human C1 Inhibitor”, 2 entries
  • “rhC1INH”, 1 entry
  • “Recombinant human C1 inhibitor”, 1 entry
  • “recombinant human C1 inhibitor”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.